American Century Companies’s Fate Therapeutics FATE Stock Holding History

American Century Companies’s Portfolio FATE Stock Details FATE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$213K	Buy	+78,919	New	+$146K	﹤0.01%	2768
2025 Q1	–	Sell	-197,704	Closed	-$326K	–	2908
2024 Q4	$326K	Buy	197,704 +12,295	+7%	+$31K	﹤0.01%	2655
2024 Q3	$649K	Buy	185,409 +19,154	+12%	+$74.5K	﹤0.01%	2382
2024 Q2	$545K	Buy	166,255 +34,676	+26%	+$152K	﹤0.01%	2410
2024 Q1	$966K	Buy	131,579 +78,597	+148%	+$486K	﹤0.01%	2164
2023 Q4	$198K	Buy	52,982 +15,920	+43%	+$37.6K	﹤0.01%	2696
2023 Q3	$78.6K	Buy	37,062 +15,848	+75%	+$52.5K	﹤0.01%	2754
2023 Q2	$101K	Buy	+21,214	New	+$117K	﹤0.01%	2675
2023 Q1	–	Sell	-327,880	Closed	-$3.31M	–	2677
2022 Q4	$3.31M	Buy	327,880 +90,990	+38%	+$1.71M	﹤0.01%	1384
2022 Q3	$5.31M	Buy	236,890 +1,655	+0.7%	+$47.8K	﹤0.01%	1086
2022 Q2	$5.83M	Buy	235,235 +18,560	+9%	+$512K	﹤0.01%	1078
2022 Q1	$8.4M	Buy	216,675 +37,090	+21%	+$1.44M	0.01%	959
2021 Q4	$10.5M	Buy	179,585 +42,141	+31%	+$2.39M	0.01%	863
2021 Q3	$8.15M	Buy	137,444 +7,290	+6%	+$572K	0.01%	902
2021 Q2	$11.3M	Buy	130,154 +332	+0.3%	+$26.8K	0.01%	786
2021 Q1	$10.7M	Buy	129,822 +117,395	+945%	+$11.2M	0.01%	765
2020 Q4	$1.13M	Buy	+12,427	New	+$772K	﹤0.01%	1225

Other funds holding FATE

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

American Century Companies's FATE Position: Q2 2026 in Review

American Century Companies opened a new position in Fate Therapeutics (FATE) in Q2 2026: 78,919 shares worth $213K. The stake represents ﹤0.01% of the portfolio and ranks #2768 among its holdings. This is a return to the name: American Century Companies previously reported a position in FATE as recently as Q4 2024.

American Century Companies first reported a position in FATE in Q4 2020 and has held it in 17 quarters since. The position peaked at $11.3M in Q2 2021. 156 funds tracked by Wall St. Rank hold FATE as of Q2 2026.

American Century Companies held 78,919 shares of Fate Therapeutics worth $213K as of Q2 2026.
Fate Therapeutics was a new American Century Companies position in Q2 2026.
Fate Therapeutics made up ﹤0.01% of American Century Companies's portfolio in Q2 2026, its #2768 holding.
American Century Companies first reported a position in Fate Therapeutics in Q4 2020 and has held it in 17 quarters since.
American Century Companies's Fate Therapeutics position peaked at $11.3M in Q2 2021.
156 funds tracked by Wall St. Rank held Fate Therapeutics as of Q2 2026.

Based on American Century Companies's 13F filing for Q2 2026, filed 12 Aug 2026.